---
title: "Kisqali (ribociclib), all indications: Safety questions"
description: "Safety questions on Kisqali (ribociclib) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings. Questions: What are the warnings and precautions for Kisqali? What are the contraindications for Kisqali? Can Kisqali cause severe skin reactions? 3 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/kisqali/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Kisqali (ribociclib), all indications: Safety questions

Manufacturer: Novartis Pharmaceuticals Corporation  
Prescribing information: [Kisqali](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf)  
Indication pages: [HR-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/medical-information/kisqali--hr-positive-her2-negative-advanced-or-metastatic-breast-cancer)

## Warnings

<a id="kisqali-warnings"></a>

### What are the warnings and precautions for Kisqali?

> “• Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life threatening, or 
> fatal ILD/pneumonitis can occur with KISQALI treatment. Monitor for 
> pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and
> evaluate patients with new or worsening respiratory symptoms suspected to 
> be due to ILD/pneumonitis. Permanently discontinue KISQALI in patients
> with recurrent symptomatic or severe ILD/pneumonitis. (2.2, 5.1) 
> • Severe Cutaneous Adverse Reactions (SCARs): SCARs including Stevens-
> Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug-
> reaction with eosinophilia and systemic symptoms (DRESS) can occur 
> with KISQALI treatment. Permanently discontinue KISQALI in patients
> with SCARs or other life-threatening cutaneous reactions. (2.2, 5.2) 
> • QT Interval Prolongation: KISQALI has been shown to prolong the QT
> interval in a concentration-dependent manner. Monitor electrocardiograms
> (ECGs) and electrolytes prior to initiation of treatment with KISQALI.
> Repeat ECGs at approximately Day 14 of the first cycle, and as clinically 
> indicated. Monitor electrolytes at the beginning of each cycle for 6 cycles,
> and as clinically indicated. Avoid using KISQALI with drugs known to
> prolong QT interval and/or strong CYP3A inhibitors. (2.2, 5.3, 7.1, 7.4) 
> • Increased QT Prolongation with Concomitant Use of Tamoxifen: KISQALI 
> is not indicated for concomitant use with tamoxifen. (5.4) 
> • Hepatotoxicity: Increases in serum transaminase and bilirubin levels have 
> been observed. Perform liver function tests (LFTs) before initiating
> treatment with KISQALI. Monitor LFTs every 2 weeks for the first 2
> cycles, at the beginning of each subsequent 4 cycles, and as clinically
> indicated. (2.2, 5.5) 
> • Neutropenia: Perform complete blood count (CBC) before initiating 
> therapy with KISQALI. Monitor CBC every 2 weeks for the first 2 cycles, 
> at the beginning of each subsequent 4 cycles, and as clinically indicated. 
> (2.2, 5.6) 
> • Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of 
> reproductive potential of potential risk to a fetus and to use effective
> contraception during therapy. (5.7, 8.1, 8.3)”

Source: [KISQALI: Prescribing information, page 1, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=1)

Note: The passages are from the Highlights of the Prescribing Information.

<a id="kisqali-contraindications"></a>

### What are the contraindications for Kisqali?

> “CONTRAINDICATIONS 
> None.”

Source: [KISQALI: Prescribing information, page 7, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=7)

<a id="kisqali-skin-reactions"></a>

### Can Kisqali cause severe skin reactions?

> “Severe cutaneous adverse reactions (SCARs), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis 
> (TEN), and drug-induced hypersensitivity syndrome (DiHS)/drug reaction with eosinophilia and systemic symptoms 
> (DRESS) can occur in patients treated with KISQALI [see Adverse Reactions (6.2)].  
> If signs or symptoms of severe cutaneous reactions occur, interrupt KISQALI until the etiology of the reaction has been 
> determined [see Dosage and Administration (2.2)]. Early consultation with a dermatologist is recommended to ensure 
> greater diagnostic accuracy and appropriate management.  
> If SJS, TEN, or DiHS/DRESS is confirmed, permanently discontinue KISQALI. Do not reintroduce KISQALI in patients 
> who have experienced SCARs or other life-threatening cutaneous reactions during KISQALI treatment.”

Source: [KISQALI: Prescribing information, page 8, captured 2026-11-13](https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf#page=8)

## Related pages
- [Medical information: Kisqali (ribociclib): All indications](https://www.evicenter.com/medical-information/kisqali)
- [Indication](https://www.evicenter.com/medical-information/kisqali/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/kisqali/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/kisqali/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/kisqali/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/kisqali/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/kisqali/storage-and-supply)
